Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 10/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290443 | 0.99 | CHEK1 (0.38) | CHEK1KDM1AMMP3MMP9CNR2 | |
| SCHEMBL22294213 | 0.90 | CHEK1 (0.39) | CHEK1KDM1ACNR2PIK3CDL3MBTL1 | |
| SCHEMBL16417913 | 0.90 | CHEK1 (0.39) | CHEK1KDM1ACNR2PIK3CDL3MBTL1 | |
| SCHEMBL19792454 | 0.86 | KDM1A (0.35) | CHEK1KDM1APIK3CDCPB2 | |
| SCHEMBL10290753 | 0.85 | CHEK1 (0.37) | CHEK1KDM1ACNR2PIK3CD | |
| SCHEMBL12352563 | 0.83 | CA1 (0.44) | CHEK1CNR2L3MBTL1 | |
| SCHEMBL10290154 | 0.83 | L3MBTL1 (0.42) | MMP3MMP9L3MBTL1CPB2 | |
| SCHEMBL16664133 | 0.82 | CA1 (0.43) | CHEK1CNR2L3MBTL1 | |
| SCHEMBL16417914 | 0.81 | HTT (0.48) | MMP3MMP9 | |
| SCHEMBL10290686 | 0.79 | HTT (0.47) | MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CHEK1 3485/4885KDM1A 1013/4885MMP3 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.